Levetiracetam
Product Images NDC 16590-867

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Levetiracetam (NDC 16590-867). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Stat Rx Usa Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label Image 250mg (Levetiracetam 250mg Label 320)

LEVETIRACETAM 250 mg tablet label from STAT RX USA LLC. The label shows that the package contains 60 tablets, generic for Keppra. It includes the NDC number 16590-320-60, and storage instructions to keep between 59-86 degrees F. Contains warnings about possible drowsiness or dizziness and federal law restrictions. The label also specifies it is for sample lot A235588 with a discard after 07/14.*

FDA Label Image

Label Image 500mg (Levetiracetam 500mg Label 685)

Label for Levetiracetam 500 mg tablets, containing 60 tabs. The label indicates it is a generic for Keppra and includes NDC 16590-685-60. It shows manufacturing details by Torrent Pharma Inc., Kalamazoo, MI. The label highlights a caution about drowsiness or dizziness and includes a RX only warning to keep out of reach of children. Labeler is STAT RX USA LLC, Gainesville, GA.*

FDA Label Image

Label Image 750mg (Levetiracetam 750mg Label 867)

Label for Levetiracetam 750 mg tablets, 60 count, distributed by STAT RX USA LLC. The label states it is a generic for Keppra and lists the NDC as 16590-867-60. It includes manufacturer information for Torrent Pharma Inc., Kalamazoo, MI, and contains cautionary warnings about drowsiness or dizziness. The label features storage and handling instructions, a sample lot number, and a prescription-only notice.*

FDA Label Image

Structural Formula (Levetiracetam Figure 01)

Chemical structure of levetiracetam, showing a pyrrolidone ring with attached ethyl, hydrogen, and amide groups. The image depicts the molecular connectivity of this active ingredient.*

FDA Label Image

Image (Levetiracetam Figure 02)

A bar graph comparing the percentage of patients experiencing a particular outcome across three groups: placebo, levetiracetam 1000 mg/day, and levetiracetam 3000 mg/day. The y-axis shows percent of patients, with levetiracetam groups showing higher percentages than placebo, indicated as statistically significant.*

FDA Label Image

Image (Levetiracetam Figure 03)

A bar chart displaying the percentage of patients across three groups: Placebo (6.3%), Levetiracetam 1000 mg/day (20.8%), and Levetiracetam 2000 mg/day (35.2%). Asterisks indicate statistically significant differences compared to placebo.*

FDA Label Image

Image (Levetiracetam Figure 04)

A bar graph comparing the percentage of patients for placebo and Levetiracetam 3000 mg/day, showing approximately 14.4% for placebo and 39.4% for Levetiracetam. The graph indicates statistical significance versus placebo with an asterisk.*

FDA Label Image

Image (Levetiracetam Figure 05)

A bar chart comparing the percentage of patients between placebo and Levetiracetam groups. The chart shows 19.6% for placebo (N=97) and 44.6% for Levetiracetam (N=101), with an asterisk indicating a statistically significant difference versus placebo.*

FDA Label Image

Logo (Levetiracetam Figure 06)

FDA Label Image

Logo (Levetiracetam Figure 07)

FDA Label Image

Image (Levetiracetam Figure 12)

A bar graph comparing the percentage of patients between placebo and Levetiracetam groups. The y-axis represents the percentage of patients from 0% to 100%. The placebo group (N=84) shows 45.2%, and the Levetiracetam group (N=79) shows 72.2%, with an asterisk above the Levetiracetam bar indicating statistical significance or special note.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.